Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha-2b Cream in HPV-positive cervical intraepithelial neoplasia
2008-006208-52Phase 2Completed
- Sponsor
- Helix BioPharma
- Start
- Feb 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa-2b in cervical intraepithelial neoplasia (CIN), cervical dysplasia (CIN) and human papillomavirus infection, sponsored by Helix BioPharma. Primary endpoint: Systemic levels of interferon alfa-2b. Started Feb 2009; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
cervical intraepithelial neoplasia (CIN)cervical dysplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on 2008-006208-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006208-52.